Other substances

Eltrombopag

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy (DrugBank).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials	in silico	3.31	In silico screening of potential SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.	Aug/05/2020
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate Preprint	Calu-3 human airway epithelial cells		comparable IC50 value between Calu-3 and VERO E6 cells	May/12/2020

AI-suggested references

Link	Publication date
A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia.	Nov/11/2021
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach	Feb/04/2020
Acute kidney injury and nephrotic syndrome associated with eltrombopag therapy in chronic idiopathic thrombocytopenic purpura.	Apr/07/2021
In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry	Dec/02/2021
Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report.	Apr/27/2021
Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein	May/09/2022

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04516837	Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19)	Recruiting	Phase 2	Aug/31/2020	Aug/01/2022
Alternative id - ITP-PKU020 Interventions - Drug: Eltrombopag\|Drug: rhTPO Study type - Interventional Study results - No Results Available Locations - Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 120 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - Complete response\|Response\|No response\|Relapses\|Early response\|Initial response\|Durable response\|TOR (time to response)\|DOR (duration of response)\|Treatments associated adverse events\|Reduction in bleeding symptoms

Export (.csv)